Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election of Monika Lessl and Astrid Haug as new independent members of the Board of Directors as…
Today, at 10:00 CET, Gubra A/S (“Gubra”) held an extraordinary general meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, DK-2100 Copenhagen. All proposals presented to the general meeting were adopted:Item 1Election of Monika Leesl and Astrid Haug as new members to the…
Gubra announces hereby that is has entered into a Market Maker Agreement with Sydbank A/S to act as liquidity provider on Gubra shares. The agreement is effective as of 26 October 2023 and will remain in force until terminated by…
Today, Gubra announces preliminary Q3 and 9M 2023 results for the CRO business and revises its revenue and EBIT outlook for 2023 upwards, driven by strong performance in Q3 2023 as well as current trading and solid orderbook. The 2023…
Gubra announces that it is opening its first US office on Kendall Square in Boston, the epicenter for the pharma and biotech community on the US East Coast. With more than half of the company’s CRO revenue generated in the…
GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), the board of directors hereby convenes an extraordinary general meeting to be held: ON 1 NOVEMBER 2023 AT 10:00 (CET)…
Gubra announces that a clinical trial application (CTA) for the anti-obesity amylin project has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The clinical trial is expected to receive approval from the MHRA later…
On 28 August 2023, Gubra A/S (“Gubra” or the “Company”) announced resumption of its share buy-back programme of in total 27,271 shares. The purpose of the share buy-back programme is to meet the Company’s obligations arising from its share-based incentive…
Gubra A/S (“Gubra” or the “Company”) today announces the resumption of its share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own shares. As 1,539 shares were repurchased during 30 June to…
Today, Gubra released its interim report for the first half of 2023. Organic revenue grew by 21% year-over-year for the CRO business with an adjusted EBIT-margin of 27%. FY-2023 outlook for organic revenue growth was, as communicated on 15 August…